Gore Range Capital

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.

Eirion Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of advanced prescription products for aesthetic dermatology. The company's product pipeline includes treatments aimed at addressing various conditions such as wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion is committed to meeting significant unmet clinical needs within the field, with plans to explore additional indications in the future. Through its innovative approach, Eirion Therapeutics aims to provide effective solutions for both physicians and patients dealing with aesthetic concerns.

Dorsata, Inc. is a healthcare technology company that specializes in providing an online platform for the development, sharing, and application of clinical care pathways. Founded in 2011 and headquartered in Arlington, Virginia, Dorsata's platform enhances collaboration among healthcare providers by enabling them to create and utilize defined workflows for efficient decision-making, documentation, and order entry. By leveraging clinician-developed care pathways, the company aims to improve healthcare quality and reduce costs. Additionally, Dorsata has developed a prenatal record platform that allows providers to manage electronic health records effectively, offering a user-friendly experience and a rules engine that helps create tailored care plans for patients throughout their pregnancy.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

CoreMedica Laboratories Inc. specializes in the development of blood serum separation and transportation containers tailored for various applications, including corporate wellness, epidemiological research, pharmaceutical monitoring, clinical trials, and insurance underwriting. Founded in 2010 and headquartered in Lee's Summit, Missouri, the company offers micro and dried blood collection and analysis tools. All testing of samples is conducted in its CAP-accredited and CLIA-certified laboratory, ensuring high standards of quality and accuracy in its services.

xMD Diagnostics, based in Annapolis, Maryland, specializes in the biotechnology sector, focusing on molecular diagnostics tools that enhance research and clinical laboratory practices. Formerly known as Bay Resources Development Group, the company employs advanced high-throughput microdissection technology to aid in cancer diagnosis. Its innovative tools enable the isolation and enrichment of specific cells from biopsy and other specimen samples, facilitating downstream applications such as polymerase chain reaction (PCR), genomic and proteomic analyses, next-generation sequencing (NGS), and various molecular testing methods. This technology supports pathologists, oncologists, and other medical professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

Medikly, Inc. is a Jersey City-based company founded in 2009 that specializes in providing a digital marketing platform tailored for healthcare marketers. This platform allows marketers to capture and utilize actionable insights about physicians, facilitating deeper engagement and understanding. MediklyOS, the company's key offering, enables brands to launch, execute, modify, and measure marketing campaigns effectively. By connecting healthcare marketers with physicians across various digital channels, Medikly empowers pharmaceutical brands to establish individual relationships with healthcare professionals. In addition to its platform, the company also offers consulting, support, training, integration, and campaign services to enhance marketing effectiveness and drive business value.

NovaScan, Inc. is a medical technology company based in Chicago, Illinois, focused on developing and manufacturing innovative cancer detection devices. Founded by a former Dean of the Engineering School at the University of Wisconsin Milwaukee, the company employs a unique technology based on Cole relaxation frequency to detect and stratify various types of cancer. Its product offerings include MarginScan for skin cancer detection, BiopsyScan for breast biopsy procedures, and FastScan Probe for identifying breast cancer. In addition, NovaScan provides electrical mammogram technology and a platform capable of detecting multiple cancerous conditions. The company's non-invasive approach is designed to facilitate minimally invasive procedures and enhance therapeutic dosing into live tumors, ultimately aiming to improve patient outcomes while reducing healthcare costs. NovaScan was originally incorporated as EPET, LLC in 2001.

Conversa Health, Inc. is a company that specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare providers. Founded in 2013 and headquartered in Portland, Oregon, with additional offices in New York, Research Triangle Park, and San Francisco, Conversa offers a Virtual Care and Communication Platform designed to improve efficiency, patient engagement, and clinical outcomes. Its Digital Checkup platform automates personalized messaging based on comprehensive patient profiles developed from electronic health records, biometric devices, and self-reported data. The company serves a diverse clientele, including health systems, pharmaceutical companies, payers, and health tech firms, facilitating proactive communication and management of patients in various contexts, such as chronic care, oncology, and wellness. Conversa’s automated care platform effectively engages patients, triaging them to appropriate care settings when necessary, and has been adopted by notable organizations for its COVID-19 Virtual Care Programs, which include symptom checking, patient check-ins, and lab result delivery.

NovaScan, Inc. is a medical technology company based in Chicago, Illinois, focused on developing and manufacturing innovative cancer detection devices. Founded by a former Dean of the Engineering School at the University of Wisconsin Milwaukee, the company employs a unique technology based on Cole relaxation frequency to detect and stratify various types of cancer. Its product offerings include MarginScan for skin cancer detection, BiopsyScan for breast biopsy procedures, and FastScan Probe for identifying breast cancer. In addition, NovaScan provides electrical mammogram technology and a platform capable of detecting multiple cancerous conditions. The company's non-invasive approach is designed to facilitate minimally invasive procedures and enhance therapeutic dosing into live tumors, ultimately aiming to improve patient outcomes while reducing healthcare costs. NovaScan was originally incorporated as EPET, LLC in 2001.

Dorsata, Inc. is a healthcare technology company that specializes in providing an online platform for the development, sharing, and application of clinical care pathways. Founded in 2011 and headquartered in Arlington, Virginia, Dorsata's platform enhances collaboration among healthcare providers by enabling them to create and utilize defined workflows for efficient decision-making, documentation, and order entry. By leveraging clinician-developed care pathways, the company aims to improve healthcare quality and reduce costs. Additionally, Dorsata has developed a prenatal record platform that allows providers to manage electronic health records effectively, offering a user-friendly experience and a rules engine that helps create tailored care plans for patients throughout their pregnancy.

Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.